These findings align with our results, indicating that the JNK/NRF2/HO-1 pathway may act as a critical mediator linking febuxostat-induced XOR inhibition to improved metabolic homeostasis in MASLD. This evidence concerns the gene NFE2L2 and metabolic dysfunction-associated steatotic liver disease.